The use of noninvasive positive pressure ventilation (NPPV) to treat severe asthma attacks is practiced far more frequently than what the health care community previously believed. Assessing its use was the focus of the study, “Association Between Noninvasive Positive Pressure Ventilation Use and Clinical Outcomes During a Severe Asthma Exacerbation: A Cohort Study,” published in the journal, Society of Critical Care Medicine.
Results from the new cohort study, which spans more than a decade of hospital data from New York and Florida, suggest that NPPV may also significantly improve patient outcomes.
Researchers analyzed 296,788 hospitalizations for asthma exacerbations recorded between 2006 and 2018 using the Healthcare Cost and Utilization Project’s State Inpatient Databases. Their findings revealed a sharp rise in NPPV use among both adult and pediatric patients. Among adults, usage increased from 1.2% of hospitalizations in 2006 to 7.4% in 2018. Pediatric usage showed a similar surge, rising from 0.7% to 7.1% over the same period.
To better understand how NPPV impacts patient outcomes, the research team conducted a propensity‑score–matched analysis of 41,902 ICU encounters. When comparing patients who received NPPV with similar patients who did not, the differences were striking.
Among adults, NPPV use was associated with a 52% lower risk of requiring endotracheal intubation. Pediatric patients experienced a similar trend, with NPPV use linked to a 50% lower risk of intubation.
The study also noted encouraging signs regarding mortality. Adults who received NPPV during a severe asthma attack experienced significantly improved in‑hospital survival, representing a substantial reduction in risk. The pediatric cohort showed a trend toward improved mortality but did not reach statistical significance.
According to the study’s authors, the findings highlight a potential shift in how clinicians manage respiratory distress during asthma attacks and suggest that the growing reliance on noninvasive ventilation may be both deliberate and beneficial.
While NPPV has long been a mainstay in treating conditions such as COPD or cardiogenic pulmonary edema, its effectiveness in asthma has been less clear due to limited evidence. This new analysis — one of the largest of its kind — strengthens the case for its use, especially in adult populations.
Researchers did caution, however, that causality cannot be definitively established. The consistent association between NPPV use and improved outcomes across a large, diverse dataset provides compelling support for further clinical study.
As hospitals continue to refine strategies for managing severe asthma, the study’s authors noted that the growing adoption of NPPV may represent a meaningful step forward in reducing the need for invasive interventions and improving patient survival.
